Ключевые слова
Как цитировать
Аннотация
Решение в отношении адъювантной химиотерапии при раннем (операбельном) раке молочной железы (РМЖ) в прошлом всецело принималось на основании клинико-патоморфологических признаков. Однако, с растущей осведомленностью о биологии опухоли и возможностью геномного анализа для определения молекулярного подтипа Рмж становится реальным идентифицировать больных, опухоли которых резистентны к химиотерапии или наоборот выигрывают от ее добавления. Несмотря на то, что геномный анализ позволяет некоторым больным избежать химиотерапии (особенно, пациенткам с локализованным РМЖ), подобные исследования не указывают на наиболее подходящие режимы химиотерапии. Поэтому решение о лечении должно основываться на комбинации особенностей биологии опухоли, ее стадии и признаков, характеризующих больную, - таких, как возраст и толерантность к побочным эффектам терапии.Библиографические ссылки
Семиглазов В.Ф. Опухоли репродуктивной системы: Клинические рекомендации по диагностике и лечению рака молочной железы. СПб. ЗАО “ МегаПро”. - 2013. - 236 с.
Семиглазов В.Ф. Стратегия лечения рака молочной железы, основанная на выделении биологических подтипов // Вопр. онкол. - 2011. - Т. 57. - С. 542 - 552.
Семиглазов В.Ф., Семиглазов В.В., Палтуев P.M. и др. Биологическое обоснование планирование лечения рака молочной железы // Врач. - 2012. - N11. - 11. - С. 2-4.
Albain KS, Paik S, van’t Veer I. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays // Breast. - 2009. - Vol. 18 (Suppl). - S141-S145.
Anders C.K., Hsu D.S. Broadwater G. et a1. Young age at diagnose correlates with worse prognosis and defines a subset of breast cancer witl shared patterns of gene expression // Clin Oncol. - 2008. - Vol. 26. - P. 33243330.
Berry D.A., Cirrincione C., Henderson J.C. et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer // JAMA. - 2006. - Vol. 295. - P. 1658-1667.
Bhargava R., Beriwal S., Dabbs D.J. et al. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases // Cancer. - 2010. - Vol. 116. - P. 1431-1439.
Byrski T., Gronwald J., Huzarski Т. et al. Pathologic complete response rates in young women with BRCA 1 -positive breast cancers after neoadjuvant chemotherapy // Clin oncol. - 2010. - Vol. 28. - P. 375-379.
Cheang M.C., Chia S.K., Voduc D. et al. Ki67 index, HER2 status, and prognosis of patients with luminal В breast cancer // J. Natl Cancer Inst. - 2009. - Vol. 101. - P. 736-750.
Curtis С., Shah S.P., Chin S.F. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups // Nature. - 2012. - Vol. 486. - P. 346-352.
Dawood S, Hu R, Homes MD. et al. Defining breast cancer prognosis based on molecular phenotypes: Results from a large cohort study // Breast Cancer Res Treat. - 2011. - Vol. 126. - P. 185-192.
Desmedt C, Di Leo A, de Azambuja E. et al. Multifactorial approach to predicting resistance to anthracyclines // Clin oncol. - 2011. - Vol. 29. - P. 1578.
Di Leo A, Desmedt C, Bartlett JM. et al. HER2 and TOP2A as predictive markers for anthracyline-containing chemotherapy regimens as adjuvant treatment of breast cancer: meta- analysis of individual patient data // Lancet oncol. - 2011. - Vol. 12. - P. 1134-1142.
Dowsett M, Cuzick J, Wale C. et al. Prediction of risk of distant recurrence in receptor using the 21-gene recurrence score in node-negative and node. positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study // Clin oncol. - 2010. - Vol. 28. - P. 1829-1834.
Fisher B, Brown AM, Dimitrov NV. et al. Two months of doxorubicin-cyclophosphamide with and without inserval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project R-15 // Clin oncol. - 1990. - Vol. 8. - P. 1483-1496.
Goldhirsch A, Wood WC, Coates AS. et al. Strategies for subtypes- dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 // Ann oncol. - 2001. - Vol. 22. - P. 1736-1747.
Huang ZH, Li LH, Hua D. Quantitative analysis of plasma circulating DNA at diagnosis and during follow-up of breast cancer patieois // Сancer Lett. -2006. - Vol. 243. - P. 64-70.
International Breast Cancer Study Group (IBCSG). Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial // J. Natl Cancer Inst. - 2002. - Vol. 94. - P. 1054-1065.
Jones S, Collea RPOratz R.et al. Preliminiry toxicity results of a phase II trial of adjuvant docetaxel/cyclophosphamide plus trastuzumab in HER2+ early stage breast cancer // Cancer Res. - 2009. - Vol. 69 (abstr 2111).
Jones SE, Savin MA, Holmes FA. et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer // Clin Oncol. - 2006. - Vol. 24. - P. 5381-5387.
Muss HB, Berry DA, Cirrincione CT. el al. Toxicity of older and young. patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Groiup В Experience // Clin Oncl. - 2007. - Vol. 25. - P. 3699-3704.
Muss HB. Adjuvant treatment of elderly breast cancer patients // Breast. - 2007. - Suppl. 16 (2). - S. 159-S165.
Muss HB. Berry DA, Cirrincione CT. et al. Adjuvant chemotherapy older women with early-stage breast cancer // N Engl J Med. 2009 vol. 36 pp. 2055-2065.
Paik S, Shak S, Tang G. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. - 2004. - Vol. 351. - P. 2817-2826.
Paik s, Tang G, shak s. et al. Gene expression and benefit of chemotherару in women with node-negative, estrogen-receptor-positive breast cancer // Clin Oncol. - 2006. - Vol. 24. - P. 3726-3734.
Pierga JY, Bidard FC. Mathiot C. et al. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial // Clin Cancer Res. - 2008. - Vol. 14. - P. 7004-7010.
Rack BK, Schindlbeck С. Andergassen A. et al. Use of circulating tumor cells (CTC) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict risk of relapse: The SUCCESS trial // Clin Oncol.- 2010. - Vol. 28. -15s (suppl; abstr 1003).
Shulman LN, Cirrincione CT, Berry DA. et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group В 40101 // Clin Oncol. - 2012. - Vol. 30. - P. 4071-4076.
Silver DP, Richardson AL, Eklund AC. et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer // Clin Oncol. - 2010. - Vol. 28. - P. 1145-1153.
Slamon D. Eiermann W, Robert N. et al. Adjuvant trastuzumab in HER2-positive breast cancer // N Engl J Med. - 2011. - Vol. 365. - P. 1273-1283.
Sorlie T. Perou CM, Tibshirani R. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications // Proc Natl Acad Sci (USA). - 2001. - Vol. 98. - P. 10869-10874.
Sotiriou C., Wirapati P., Loi S. et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis // Natl Cancer Inst. - 2006. - Vol. 98. - P. 262-272.
Tavassoli FA, Devilee Р (eds). Pathology 6. Genetics of Tumours of the Breast and Female Genital Organs. Lyon; International Agency for Research on Cancer Press; 2003.
Turner N., Biganzoli B., Malorni L., Di Leo.A. Adjuvant chemotherapy: which patients, what regiment? ASCO Educational Book. - 2013. - P. 3-8.
van t Veer LJ, Dai H, van de Vijver MJ. et al. Gene expression profiling predicts clinical outcome of breast cancer // Nature. -2002. - Vol. 415. - P. 530-536.
Wu X, Somlo G, Yu X et al. De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer // Transl Med. - 2012. -Vol. 10. - P 42.
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-NoDerivatives» («Атрибуция — Некоммерческое использование — Без производных произведений») 4.0 Всемирная.
© АННМО «Вопросы онкологии», Copyright (c) 2014